Swiss

ITI Treatment guide 2 – Loading Protocols in Partially Dentate Patients

The ITI (International Team for Implantology) has released their second hardcover treatment guide. Volume 2 of the ITI Treatment Guide deals with the clinical aspects of various treatment protocols in the anterior and posterior regions for both single- and multi-tooth gaps as well as for free-end situations. Besides an analysis of recent literature on the topic of “Loading protocols in implant dentistry”, volume 2 of the ITI Treatment Guide provides the practitioner with a framework for risk analysis and subsequent

Nobel Overdenture

Nobel Biocare has released a one-piece implant design `NobelOverdenture` for use in edentulous situations. It features narrow diameter and one piece for ease of handling. It promises to deliver a cost-effective option to secure dentures.

Straumann`s new Bone Level Implant

Straumann has released their new implant – the `bone level` implant. It features the SLActive surface all the way up to the top of the implant. The abutments are anatomically shaped and feature a `platform-switching` concept. It appears that this design is a response to concerns regarding esthetics and recession with implants in the esthetic zone. Straumann reports that `Intermediate data from the first clinical study show excellent esthetic results with regard to both hard and soft tissues indicating a

Straumann`s Drill Stops

Straumann has released a set of drill stops for use with their single-use implant drills. The color coded drill stops come in a kit designed for a specific depth e.g 8mm. The small size of the drill stops offer an optimum view of the treatment area and openings on the drill stops facilitate irrigation and removal of bone chips.

Nobel Biocare CEO Replaced

Nobel Biocare`s CEO Heliane Canepa has been replaced. Domenico Scala has been named its new chief executive, replacing Heliane Canepa, as of Sept 1, 2007. Nobel Biocare Chairman, Rolf Soiron, explained the decision to replace Canepa by saying: `An international company of this size should not be so greatly identified with a single person as has been the case at Nobel Biocare`. Swiss Sunday paper, SonntagsZeitung, reported Heliane Canepa has come under fire over allegations that the Swedish-Swiss dental implant

NobelActive

Nobel Biocare released another implant design called `NobelActive` at their world conference in Las Vegas. This design features a new thread pattern. They claim that: `The one-stage implant features a unique shape and a new thread design with a “self-drilling” capability to facilitate drilling protocols in areas of narrower osteotomy. The product is easy to use and provides high initial stability and good outcomes. NobelActive(tm) has been designed for increased soft tissue volume at the head of the implant, resulting

US ban on Biora Products costs Straumann 10 million Swiss Francs

The continuing FDA ban on importation of Biora`s Emdogain and Bone Substitute has cost parent company Straumann 10 million Swiss francs (8.14 million US$). Straumann chief executive Gilbert Achermann described the loss as `painful`. He furthermore stated that `The US FDA will reinspect our facility in Malmo, but we are not in a position to say when this will happen, If all goes well`, Biora products `could be reintroduced in the US in the first quarter of this year,` Additionally,

Nobel Biocare`s Ti-Unite to feature BMP-2 coating

Swiss implant manufacturer Nobel Biocare has signed an exclusive agreement with Wyeth Pharmaceutical manufacturer of Bone Morphogenic Protein rhBMP-2. They claim that: `TiUnite(r) will serve as the foundation for the next generation of dental implants with the potential of eliminating the need to graft and use of membranes. Nobel Biocare is currently in clinical testing of an implant designed to create its own bone. This implant will be treated with a bone morphogenetic protein rhBMP-2 (a recombinant version of a

Novartis acquires 10% stake in Thommen Medical

Novartis, the Swiss pharmaceutical giant has taken a 10% stake in Swiss dental implant manufacturer Thommen Medical. According to a press release, Novartis`s stake will rise to 20% later in the summer. Andreas Stutz, Thommen Medical CEO says: “Novartis is a strategic partner for us. This opens completely new possibilities in the area of research. The understanding of soft-tissue and bone biology becomes more and more important for the producers of dental implants. Furthermore, we see the interest of Novartis

Straumann Twist Drill Pro

Straumann has updated their wide diameter implant twist drill design with a rounded apical profile ending in a flat tip to allow for more accurate osteotomy preparation. They claim that `the rounded flat-end tip facilitates safe drill positioning and ensures secure drill centering in the implant bed. The defined direction is maintained throughout the entire drilling process.`